证券代码:002399 证券简称:海普瑞 深圳市海普瑞药业集团股份有限公司投资者关系活动记录表 编号: 2018-002 | --- | --- | --- | |-----------------------------|-------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | 投资者关系活动 ■特定对象调研 | □分析师会议 | | 类别 | □媒体采访 | 口业绩说明会 | | | 口新闻发布会 | 口路演活动 | | | □现场参观 | | | | | 口其他 (请文字说明其他活动内容) | | 参与单位名称及 | | 汇添富基金:付鹏飞;南工资产:许育汕;中荷人寿:葛静、 | ...

证券代码：002399 证券简称：海普瑞 | --- | --- | --- | |-----------------------------|---------------------------------------|----------------| | | | 编号：2018-003 | | 投资者关系活动 | ■特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 安信证券：梁静静 | | | 人员姓名 | 平安证券：倪亦道 | | | 时间 2018 年 5 月 18 | | 日 14:00-15:00 | | | 地点 松坪山郎山路 21 号公司会议室 | | | 上市公司接待人 员姓名 | 步海华、黄克雨 | | | 投资者关系活动 主要内容介绍 | 了解公司生产经营情况 | | | | 附件清单（如有） 安信证券调研会议纪要 | | | | 日期 2018 年 5 月 18 日 | | 深圳市海普瑞药业集团股份有限公 ...

证券代码：002399 证券简称：海普瑞 深圳市海普瑞药业集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|---------------------------------------|----------------| | | | 编号：2018-008 | | 投资者关系活动 | ■特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 人员姓名 | 招商证券：李点典 | | | | | | | | 时间 2018 年 6 月 19 日 14:00-15:00 | | | | 地点 松坪山郎山路 21 号公司会议室 | | | 上市公司接待人 员姓名 | 白琼 | | | 投资者关系活动 主要内容介绍 | 了解公司生产经营情况 | | | | 附件清单（如有） 招商证券调研会议纪要 | | | | 日期 2018 年 6 月 19 日 | | 会议 ...

(A)Hepalink 证券代码:002399 证券简称:海普瑞 深圳市海普瑞药业集团股份有限公司投资者关系活动记录表 编号: 2018-006 | --- | --- | --- | --- | --- | --- | |-----------------------------|---------------------------------|--------------|-------|-------|-------| | | | | | | | | | 投资者关系活动 ■特定对象调研 | 口分析师会议 | | | | | 类别 | 口媒体采访 | 口业绩说明会 | | | | | | 口新闻发布会 | 口路演活动 | | | | | | □现场参观 | | | | | | | 口其他 (请文字说明其他活动内容) | | | | | | 参与单位名称及 | 蓝桥资本:邓聪 | | | | | | 人员姓名 | 广证恒生:李安飞 华孚时尚:陈金东 | | | | | | 时间 | 2018年 5 月 31日 09:30-11:00 | | | | | | 地点 | 松坪山郎山路 21 号公司会议室 | ...

A Henalink 证券代码:002399 证券简称:海普瑞 深圳市海普瑞药业集团股份有限公司投资者关系活动记录表 编号:2018-010 | --- | --- | --- | |-----------------------------|---------------------------------|-------------| | | | | | 投资者关系活动 \| | ■特定对象调研 | □分析师会议 | | 类别 | 口媒体采访 | □业绩说明会 | | | 口新闻发布会 | 口路演活动 | | | □现场参观 | | | | 口其他 (请文字说明其他活动内容) | | | 参与单位名称及 | 长城证券:赵浩然、彭学龄 | | | 人员姓名 | 平安大华:毛元江 | | | | 翰川投资:邱馨慧 | | | | 岭南资本:张罗强 深圳蓝桥:邓聪 | | | | 诺安基金:丁云波 | | | 时间 | 2018年 10月 16 日 10:00-11:30 | | | 地点 | 松坪山郎山路 21 号公司会议室 | | | 上市公司接待人 员姓名 | 步海华、白琼 | | | 投资者关系活动 主 ...

(A Hepalink 证券代码:002399 证券简称:海普瑞 深圳市海普瑞药业集团股份有限公司投资者关系活动记录表 编号: 2019-002 | --- | --- | --- | |-----------------------------|--------------------------------------------|--------------| | | | | | 投资者关系活动 \| | ■特定对象调研 | □分析师会议 | | 类别 | □媒体采访 | 口业绩说明会 | | | 口新闻发布会 | 口路演活动 | | | □现场参观 | | | | 口其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 广证恒生:唐爱金、冯俊曦 | | | 人员姓名 | 广州证券:邓聪 | | | | 国信证券: 宋逸雄 | | | | 恒生银行:林洋 | | | | 广东阿米巴基金管理有限公司: 雷小艳 | | | 时间 | 2019.02.28 10:00-12:00 | | | 地点 | 松坪山郎山路 21 号公司会议室 | | | 上市公司接待人 员姓名 | 步海华、张亚君、邹美娟 ...

C Hepalink 证券代码:002399 证券简称:海普瑞 深圳市海普瑞药业集团股份有限公司投资者关系活动记录表 编号:2019-003 | --- | --- | --- | --- | |-----------------------------|---------------------------------------------------------|-------------|-------| | | | | | | | 投资者关系活动 \| ■特定对象调研 | □分析师会议 | | | 类别 | □媒体采访 | □业绩说明会 | | | | 口新闻发布会 | 口路演活动 | | | | □现场参观 | | | | | 口其他 (请文字说明其他活动内容) | | | | 参与单位名称及 | 平安证券:叶寅 | | | | 人员姓名 | 海富通基金管理有限公司:刘洋 东吴证券股份有限公司:许汪洋 | | | | 时间 | 2019.03.06 10:00-12:00 | | | | 地点 | 松坪山郎山路 21 号公司会议室 | | | | 上市公司接待人 员姓名 | 步海华、张亚君、邹美娟 ...

证券代码: 002399 证券简称:海普瑞 深圳市海普瑞药业集团股份有限公司投资者关系活动记录表 编号: 2019-00 | | --- | --- | --- | |-----------------------------|---------------------------------|-------| | | | | | | □分析师会议 | | | 投资者关系活动类\|□媒体采访 | □业绩说明会 | | | 别 | □路演活动 | | | | | | | | 口其他 (请文字说明其他活动内容) | | | 参与单位名称及人 员姓名 | 西南证券:陈铁林、张祝源 | | | 时间 | 2019.01.10 14: 30-16: 30 | | | 地点 | 松坪山郎山路 21 号公司会议室 | | | 上市公司接待人员 姓名 | 步海华、张亚君、邹美娟 | | | 投资者关系活动主 要内容介绍 | 了解公司生产经营情况 | | | 附件清单（如有) | 西南证券调研会会议纪要 | | | 日期 | | | 会议纪要 | --- | --- | --- | --- | |------------|-- ...

Revenue and Profit - Revenue for Q3 2022 reached ¥1,636,515,303.73, an increase of 7.83% year-over-year, while year-to-date revenue totaled ¥5,395,177,444.06, up 16.49% compared to the previous year[7] - Net profit attributable to shareholders for Q3 2022 was ¥141,118,351.11, reflecting a 14.41% increase year-over-year, with a year-to-date net profit of ¥652,257,852.66, up 41.33%[7] - Basic earnings per share for Q3 2022 were ¥0.0962, a 14.39% increase from the same period last year, while year-to-date earnings per share reached ¥0.4445, up 41.34%[7] - Total operating revenue for the period reached ¥5,395,177,444.06, an increase of 16.6% compared to ¥4,631,282,401.56 in the previous period[33] - Net profit for the period was ¥650,063,599.37, representing a 42.3% increase from ¥457,062,547.37 in the same period last year[36] - The total comprehensive income attributable to the parent company was approximately CNY 1,028,077,003.26, an increase from CNY 464,586,111.21 in the previous period[39] - Basic and diluted earnings per share were both CNY 0.4445, up from CNY 0.3145 in the previous period[39] Assets and Liabilities - Total assets as of the end of Q3 2022 amounted to ¥21,469,099,221.29, representing a 12.36% increase from the end of the previous year[7] - The company's total liabilities increased by 61.53% year-over-year, with short-term borrowings reaching ¥3,046,828,803.75[12] - Total liabilities increased to ¥8,997,212,942.94, up 18.6% from ¥7,584,859,851.21 in the previous period[32] - The total equity attributable to shareholders of the parent company reached ¥12,361,047,485.93, an increase from ¥11,411,354,455.88, reflecting an 8.3% growth[32] - The company's goodwill increased to ¥2,396,630,597.70, up from ¥2,152,201,146.76, indicating a growth of 11.4%[29] - Deferred income tax assets rose to ¥135,250,767.58, compared to ¥121,717,732.33 in the previous period, marking an increase of 11.0%[29] Cash Flow - The company reported a significant increase in cash flow from operating activities, with a net cash flow of -¥719,281,089.84 year-to-date, reflecting a decline of 686.10%[7] - The net cash flow from operating activities decreased by 686.10% to -719,281,089.84 RMB compared to the same period last year, primarily due to increased cash payments for goods and services exceeding cash received from sales[17] - The net cash flow from investing activities dropped by 99.77% to 2,353,780.24 RMB, significantly lower than the previous year's high due to the receipt of Kymab equity transfer funds last year[17] - The net cash flow from financing activities increased by 307.43% to 970,216,608.77 RMB, mainly due to a rise in cash received from borrowings[17] - The total cash and cash equivalents decreased by 60.32% to 263,874,379.54 RMB, influenced by the combined reduction in cash flow from operating and investing activities[17] - Cash inflow from operating activities totaled CNY 6,083,780,203.37, compared to CNY 5,014,053,179.06 in the previous period[40] - Cash outflow from operating activities was CNY 6,803,061,293.21, leading to a net cash flow from operating activities of CNY -719,281,089.84, down from CNY 122,722,548.80 in the previous period[40] - Cash inflow from investment activities was CNY 4,584,605,355.61, a decrease from CNY 4,925,011,837.57 in the previous period[43] - Cash outflow from investment activities was CNY 4,582,251,575.37, compared to CNY 3,887,683,914.80 in the previous period[43] - Cash inflow from financing activities was CNY 4,939,819,789.90, up from CNY 2,890,440,715.27 in the previous period[43] - The net cash flow from financing activities was CNY 970,216,608.77, a significant improvement from CNY -467,723,955.63 in the previous period[43] - The ending balance of cash and cash equivalents was CNY 1,743,507,813.58, down from CNY 1,995,176,277.51 in the previous period[43] Inventory and Expenses - Inventory increased by 38.15% year-over-year to ¥6,503,409,988.32, driven by strategic raw material reserves and anticipated market demand growth[12] - Operating costs amounted to ¥4,468,505,243.35, up 8.9% from ¥4,100,533,785.75 in the prior period[33] - Research and development expenses for Q3 2022 were ¥166,593,528.66, a 52.92% increase compared to the same period last year, indicating a focus on innovation[13] - Research and development expenses increased to ¥166,593,528.66, up 53.1% from ¥108,939,733.97 in the previous period[33] - Inventory levels rose significantly to 6,503,409,988.32 RMB from 4,707,548,592.43 RMB, reflecting increased stock levels[26] - The long-term equity investments decreased to 1,062,848,714.35 RMB from 1,146,464,930.04 RMB, indicating a reduction in long-term investment holdings[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,203, with the top ten shareholders holding significant stakes, including Shenzhen Le Ren Technology Co., Ltd. at 32.31% and Urumqi Jintian Soil Equity Investment Partnership at 27.81%[18] - The cash and cash equivalents as of September 30, 2022, amounted to 2,947,231,848.07 RMB, slightly up from 2,944,257,086.12 RMB at the beginning of the year[26] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[24] - The company reported a foreign currency translation difference of CNY 312,215,768.46, compared to CNY 14,691,546.20 in the previous period[39]

Financial Performance - Total revenue for Q3 2022 reached ¥1,636,515,303.73, representing a year-over-year increase of 7.83%[3] - Net profit attributable to shareholders for Q3 2022 was ¥141,118,351.11, up 14.41% compared to the same period last year[3] - The net profit excluding non-recurring gains and losses for Q3 2022 was ¥122,989,129.35, showing a slight decrease of 0.23% year-over-year[3] - Basic earnings per share for Q3 2022 were ¥0.0962, an increase of 14.39% year-over-year[3] - The company achieved a total sales revenue of RMB 5,395.2 million, an increase from RMB 4,631.3 million in the same period last year, representing a growth of 16.6%[13] - Gross profit for the period was RMB 1,740.6 million, compared to RMB 1,456.6 million in the previous year, indicating a growth of 19.5%[13] - Net profit attributable to shareholders was RMB 652.3 million, up from RMB 461.5 million year-on-year, reflecting a growth of 41.3%[13] - Operating profit rose by 50.33% to RMB 841.9 million, driven by increased gross profit and foreign exchange gains[9] - Net profit for the period was ¥650,063,599.37, representing a 42.3% increase from ¥457,062,547.37 in the previous period[27] Cash Flow - Cash flow from operating activities showed a significant decline, with a net cash outflow of ¥719,281,089.84, a decrease of 686.10% compared to the previous year[3] - The net cash flow from operating activities decreased by 686.10% to a negative RMB 719.3 million, primarily due to increased cash payments for goods and services[11] - Cash inflow from operating activities for the current period is 6,083,780,203.37 RMB, up from 5,014,053,179.06 RMB in the previous period, representing an increase of approximately 21.4%[30] - Cash outflow from operating activities for the current period totals 6,803,061,293.21 RMB, compared to 4,891,330,630.26 RMB in the previous period, indicating a significant increase of approximately 39.1%[31] - The net cash flow from operating activities for the current period is -719,281,089.84 RMB, a decrease from 122,722,548.80 RMB in the previous period[31] - Cash inflow from financing activities for the current period is 4,939,819,789.90 RMB, compared to 2,890,440,715.27 RMB in the previous period, indicating an increase of approximately 71.0%[32] - The net cash flow from financing activities for the current period is 970,216,608.77 RMB, a significant improvement from -467,723,955.63 RMB in the previous period[32] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥21,469,099,221.29, reflecting a 12.36% increase from the end of the previous year[3] - The total current assets as of September 30, 2022, amount to ¥12,883,683,738.73, an increase from ¥10,769,653,462.96 at the beginning of the year[22] - Total liabilities rose to ¥8,997,212,942.94, up 18.6% from ¥7,584,859,851.21 in the previous period[25] - The total equity attributable to shareholders reached ¥12,361,047,485.93, an increase of 8.3% from ¥11,411,354,455.88[25] - The total liabilities to equity ratio stands at approximately 0.73, indicating a balanced capital structure[25] Inventory and Borrowings - Inventory increased by 38.15% year-over-year, reaching ¥6,503,409,988.32, attributed to strategic raw material reserves and anticipated market demand growth[6] - Short-term borrowings rose by 61.53% to ¥3,046,828,803.75, primarily due to increased bank loans during the reporting period[6] - The company's short-term borrowings have risen to ¥3,046,828,803.75 from ¥1,886,284,700.56, reflecting an increase of approximately 61.4%[23] Research and Development - Research and development expenses increased by 52.92% to RMB 166.6 million, attributed to direct investment increases[8] - Research and development expenses increased to ¥166,593,528.66, compared to ¥108,939,733.97 in the prior period, reflecting a growth of 53.1%[26] Market Performance - The heparin industry chain business achieved sales revenue of RMB 4,611.3 million, a 13.6% increase from RMB 4,054.5 million in the same period last year[14] - Sales revenue from enoxaparin sodium formulations reached approximately RMB 2,315.2 million, representing a 31.1% growth compared to RMB 1,765.6 million last year, with sales volume increasing by 32.7%[14] - The European market sales volume grew by 26.2%, despite currency fluctuations impacting sales[14] - The U.S. market saw a 144.6% increase in sales volume through a combination of partner and self-operated sales models[14] - Sales from the heparin raw material business amounted to approximately RMB 2,208.6 million, a 1.5% increase from RMB 2,176.0 million last year[14] - CDMO business sales reached approximately RMB 749.9 million, a 37.5% increase from RMB 545.0 million in the previous year[15] Strategic Initiatives - The company continues to strengthen relationships with existing clients and optimize supply chain management to support growth objectives[13] - The company plans to strengthen marketing and market development for enoxaparin sodium formulations, particularly in Europe and the U.S.[17] - The company aims to enhance its supply chain management and maintain cost advantages to improve financial performance amid economic uncertainties[16] - The company will continue to explore new customer opportunities in the CDMO sector and enhance service capabilities in microbiology[17] - The company is committed to optimizing its global industrial chain deployment to achieve sustainable profitability[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 26,203, with the top 10 shareholders holding a combined 78.69% of shares[18] - Shenzhen Le Ren Technology Co., Ltd. holds 32.31% of shares, amounting to 474,029,899 shares, while Urumqi Jintian Soil Equity Investment Partnership holds 27.81% with 408,041,280 shares[19] - The top shareholder relationships indicate that Shenzhen Le Ren Technology Co., Ltd. and Urumqi Jintian Soil Equity Investment Partnership are linked through common partners, Li Li and Li Tan[19]